Clinical Trials
0
0 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
N/A
No trial phase data available
No trial data available
No trial data available
No approval data available
- Huons Biopharma's Chinese partner iMaker Technology received NMPA approval for Hutox, a type A botulinum toxin product, marking the second Korean company to enter China's botulinum toxin market. - The 100-unit Hutox injection completed Phase 3 clinical trials in China for treating moderate to severe facial wrinkles and received commercialization approval approximately 1 year and 7 months after NDA submission. - Hutox becomes the seventh botulinum toxin product commercialized in China, joining established competitors including AbbVie's Botox, Hugel's Letybo, and Ipsen's Dysport. - iMaker plans to leverage its established distribution network across China and utilize its own filler production facilities to enable rapid market launch and stable supply.
- Gilead Sciences has initiated legal actions at the Unified Patent Court and European Patent Office to challenge a patent held by China's Academy of Military Medical Sciences that threatens remdesivir sales. - The disputed European patent EP 3 854 403 protects the use of substituted aminopropionate compounds for treating SARS-CoV-2 infections, potentially blocking Gilead's COVID-19 drug Veklury. - The pharmaceutical giant is pursuing a dual strategy with both UPC revocation proceedings and EPO opposition to expedite patent invalidation, potentially receiving a decision by next summer. - This case represents part of a growing trend of pharmaceutical companies using the UPC for patent revocation actions, following similar moves by Astellas, Sanofi, and Pfizer against competitors' patents.
• Vensica Medical secured $11 million in funding to support Phase 2 clinical trials of its needle-free botulinum toxin A (Xeomin®) delivery system for overactive bladder (OAB). • The funding round was led by Israel Biotech Fund (IBF), with participation from Merz and Laborie, to advance a minimally invasive OAB treatment option. • Vensica's technology delivers Xeomin® directly to the bladder wall, potentially offering a more comfortable alternative to traditional injections for OAB patients. • The strategic partnership with Merz grants Vensica exclusive rights to use Xeomin® in needle-free applications for urologic indications, enhancing its clinical development.
• Vensica Medical secured $11 million in funding to support Phase 2 clinical trials of its needle-free botulinum toxin A (Xeomin®) delivery system for overactive bladder (OAB). • The funding round was led by Israel Biotech Fund (IBF), with participation from strategic partners Merz and Laborie, to advance minimally invasive OAB treatment. • Vensica's technology delivers Xeomin® directly to the bladder wall, offering a potentially more comfortable alternative to traditional injections for OAB patients. • The collaboration with Merz grants Vensica exclusive rights to use Xeomin® in needle-free applications for urologic indications, enhancing its next-generation urology treatments.
• Vensica Medical secured $11 million in funding to support Phase 2 clinical trials of its needle-free botulinum toxin A (Xeomin®) delivery system for overactive bladder (OAB). • The funding round was led by Israel Biotech Fund (IBF), with participation from Merz and Laborie, to advance minimally invasive OAB treatment. • Vensica's technology delivers Xeomin® directly to the bladder wall, offering a potentially more comfortable alternative to traditional injections. • The strategic partnership with Merz grants Vensica exclusive rights to Xeomin® for needle-less urologic applications, enhancing next-generation urology treatments.
